Similarly, a loss-of-function mutation in XBP1, which prevents the proper splicing of its mRNA, has been reported in rare cases of myeloma and may be associated with resistance to proteasome inhibitors [232,233]. Here, XBP1 is linked to plasma cell myeloma.